NEW YORK–(BUSINESS WIRE)–#DisruptiveHealthcare–SC Health Corporation (“SC Health”) announced today the pricing of its initial public offering and committed capital raise of up to $222.5 million in the aggregate, comprised of […]

NEW YORK–(BUSINESS WIRE)–Pivotal Investment Corporation II (NYSE: PIC.U) (the “Company”) announced today that it priced its initial public offering of 20,000,000 units at $10.00 per unit. The units will commence […]

ICR’s Governance Solutions Practice Helps Boards Plan for Public Market Risk Prior to Going Public NEW YORK–(BUSINESS WIRE)–As issuers complete their IPOs and begin life as public companies, their shareholder […]

In an interview with Cheddar TV (at 2:05), IPO Edge Editor-in-Chief John Jannarone explains how Cowen & Company outperforms even bulge bracket investment banks as lead left manager. According to […]

NEW YORK–(BUSINESS WIRE)–Owl Rock Capital Corporation (“ORCC”), a business development company externally managed by Owl Rock Capital Advisors LLC, today announced that it plans to make an initial public offering […]

AdaptHealth is the Third Largest Distributor of Home Medical Equipment in the United States Combined Company Expected to Trade on the NASDAQ post-close NEW YORK & PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–DFB […]

WALTHAM, Mass.–(BUSINESS WIRE)–Dynatrace Holdings LLC, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial […]

When Cowen & Company is Lead Left, IPOs Tend to Outperform By John Jannarone When it comes to measuring the success of an IPO, there is often a swirl of […]

BOSTON–(BUSINESS WIRE)–$KRTX–Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced the closing of its initial public offering […]

WALTHAM, Mass.–(BUSINESS WIRE)–Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the closing of its initial public offering of 6,900,000 shares of its […]